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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a progressive lung disorder characterized by poorly
reversible airway obstruction and its pathogenesis remains largely misunderstood. Local changes of regulatory T-cell
populations in the lungs of COPD patients have been demonstrated although data concerning their pathologic role
are contrasting. The aim of our study was to evaluate the relative percentage of regulatory T-cells in the peripheral
blood of current and former smoker subjects, affected or not by COPD. Furthermore, the effect of different
concentrations of budesonide and formoterol, on regulatory T-cells has been investigated.
Methods: T regulatory lymphocytes were isolated and assessed as CD4+CD25highCD127- cells by flow cytometry
and cultured for 48 hours in the absence or in the presence of budesonide and/or formoterol at different doses.
Results: CD4+CD25highCD127- regulatory T-cells percentage was significantly reduced in COPD patients, both
current and former smokers, with respect to volunteers. Furthermore, CD4+CD25highCD127- cells of COPD patients
showed a not statistically significant response to drugs compared to healthy subjects.
Discussion: Our results evidenced a different behaviour of CD4+CD25highCD127- Treg cells in COPD patients after
in vitro treatments.
Conclusions: Based on our data, we suggested a possible role of CD4 CD25highCD127 T-cells in COPD
pathogenesis.
Keywords: Chronic obstructive pulmonary disease (COPD), Inflammation, Regulatory T-cells, Corticosteroids,
Budesonide, LABA, Formoterol
Background
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive lung disorder characterized by poorly reversible
airway obstruction. Tobacco smoking is the main etio-
logical factor inducing oxidative stress and an abnormal
inflammatory response leading to mucociliary dysfunc-
tion, airway wall thickening and pulmonary parenchymal
changes [1]. COPD pathogenesis remains largely un-
known and it appears to be the result of smoke exposure
and host/defense interaction. In balancing the efficient
recognition of pathogens and the control of immune tol-
erance, regulatory T-cells (Tregs) play a key role. Different
subtypes of Tregs exist. While the forkhead box P3 tran-
scription factor (FOXP3) is the hallmark of regulatory
function, interleukin (IL)-2 receptor α-chain (also known
as CD25) is a cell surface marker commonly used to dis-
tinguish among regulatory (CD25high), activated (CD25int),
and naive (CD25low) T-cells in humans [2]. Liu et al. have
demonstrated that the downregulation of the α-chain of
the IL-7 receptor (CD127) on the majority of the CD4
+FOXP3+ T-cells distinguishes Tregs from activated T-
cells. Low CD127 expression, combined with high expres-
sion of CD25, therefore enables better isolation and purifi-
cation of Treg populations among CD4+CD25+ T-cells. In
functional assays, CD4+CD25highCD127low T-cells are
highly suppressive [3].
Contrasting evidences have been reported concerning
different subtypes of CD4+FOXP3+ T-cells in COPD.
Plumb et al. assessed the presence of CD4+FOXP3+
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Tregs in surgically resected lung tissues from COPD pa-
tients, smokers with normal lung function and healthy
non smokers showing an increased number of CD4
+FOXP3+ cells in lymphocyte follicles in lung paren-
chyma of moderate COPD patients [4]. Roos-Engstrand
et al., analyzing the bronchoalveolar lavage fluid (BALF),
showed no significant differences in CD4+CD25+ cells
between COPD patients and the other healthy smokers
and non smokers subjects. Among CD4+ T-cells ex-
pressing CD25, smokers with normal lung function had
significantly decreased percentage of FOXP3 expression
compared with those who never smoked. Moreover, the
authors found that ex-smokers COPD patients expressed
a decreased percentage of CD127+ cells in BALF com-
pared to smoking COPD patients and the expression of
CD127 on CD4+CD25+ T-cells was increased in smokers
with normal lung function, with respect to non-smokers
[5]. Compared with never smokers, smokers with normal
respiratory function presented a greater number of regu-
latory T-cells, absent in COPD subjects [6]. Further, an
increased proportion of Tregs in the BALF was found in
smokers with COPD compared to the control group [7].
Recently, Lane et al. have found that smokers without
COPD have increased numbers of CD4+CD25+FOXP3+
Tregs in the large airways [8]. Besides, another study
demonstrated impaired Treg-mediated suppression of
CD4+ T-cell activation in a group of COPD patients with
high body mass index and similar proportions of CD4
+FOXP3+ T-cells in COPD patients compared to con-
trols [9].
Tregs have also been explored in peripheral blood.
Xiong et al. showed that CD4+CD25+, CD4+ Treg, CD8
+CD25+ and CD8+ Tregs were expressed in the periph-
eral blood of patients with acute exacerbations of COPD
with a significant correlation with age, disease’s course,
smoking index, quantity of white cells, and blood pH,
while no correlations were found between these cells
and IL-10 [10]. Barcelò et al. showed no significant dif-
ferences in peripheral blood samples among healthy
smokers, no-smokers and COPD patients, concerning
CD4+CD25+ T-cells [6].
Overall, these data underline a not well understood
role of Treg population in the pathogenesis of COPD
and further investigations are needed to evaluate the po-
tential effect of drugs on Tregs. Bronchodilators, such as
long-acting β2-agonists, and inhaled corticosteroids,
used in combination, are the recommended treatment
for moderate and severe COPD patients with frequent
exacerbations. It has been demostrated that glucocorti-
coids are able to restore the balance between inflamma-
tory and regulatory cells, increasing the proportion of
FOXP3+ Treg cells [11, 12] but, to date, not many stud-
ies assessed the effects of ß2-agonists in combination
with corticosteroids on these lymphocytes [13].
The aim of our study was to evaluate the relative per-
centage of CD4+CD25highCD127- Tregs in the peripheral
blood of current and former smoker COPD patients and
healthy volunteers. Furthermore, the in vitro effect of dif-
ferent concentrations of an inhaled corticosteroid (bude-
sonide) and a long-acting β2-agonist (formoterol), alone
and combined, in modulating CD4+CD25highCD127-
Tregs cell population has been investigated.
Methods
Study subjects
According with the protocol approved by ethical com-
mittees of IRCCS-A.O.U. San Martino-IST of Genoa,
healthy volunteers current smokers (CSHV) and never-
smokers (NSHV), and COPD patients, former smokers
(FSC) and current smokers (CSC), were enrolled from
November 2012 to December 2013 among the outpa-
tients attending at Allergy and Respiratory Diseases
Clinic of Genoa University for a scheduled visit. COPD
diagnosis and functional severity were performed ac-
cording to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) document 2011 revision [14]. In-
clusion criteria were age ≥40 years, clinical diagnosis of
COPD and symptoms for more than 2 years, forced ex-
piratory volume in the 1st second (FEV1)/forced vital
capacity (FVC) post-bronchodilator lower than 70 %,
FEV1 between 50-80 % of normal predicted, smoking
history of at least 10 pack years, on treatment with long
acting bronchodilators. Patients having history of asthma
and/or allergic rhinitis before the age of 40 years, or suf-
fering from cancer, infections, autoimmune diseases and
other immune-related diseases were excluded. No pa-
tients treated with chemotherapics, immunosuppressors,
oral steroids and antibiotics in the 4 weeks before the
enrollment, were recruited. CSHV and NSHV were ≥
40 years of age with normal spirometry according to
American Thoracic Society (ATS)/European Respiratory
Society (ERS) criteria. Written informed consent was ob-
tained from all participants before study.
Isolation of peripheral blood mononuclear cells and
immunophenotyping
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from the peripheral blood of COPD patients,
CSHV and NSHV by means of a density gradient centri-
fugation (Lympholyte; Cedarlane, Burlington, USA).
PBMCs were suspended in RPMI 1640 cell culture
medium (Euroclone S.p.A.; Pero, Milan, Italy) and viable
cell counts obtained. Regulatory lymphocytes were
stained and assessed as CD4+CD25highCD127- cells.
Their percentage as a proportion of the total CD4+ cells
was tested by flow cytometry before treatments (time
t0). The following mAbs were used: CD4-FITC, CD25-
PE and CD127-PC5 (Immunotech; Beckman Coulter,
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Marseille, France). Tregs CD4+CD25highCD127- were
gated from CD4+ T-cells (Fig. 1). 100.000 events for each
sample were acquired using the Attune Acoustic Focus-
ing Cytometer (Life Technologies, Carlsbad, USA) and
the analysis was performed with Attune Cytometric Soft-
ware 2.1. The results were expressed as percentage of
gated CD4+ cells.
Cell culture and drug treatment
We analyzed CD4+CD25highCD127- cells population by
flow cytometry using an incubation time of 48 hours ac-
cording with previously published experiments [15].
Fresh PBMCs were cultured in 24-well round-bottomed
microtiter plate at 2X106 cells/well in RPMI 1640 (Euro-
clone S.p.A.; Pero, Milan, Italy) supplemented with 10 %
heat-inactivated Human AB Serum (Euroclone S.p.A.;
Pero, Milan, Italy), 1 % penicillin/streptomycin (Euro-
clone S.p.A.; Pero, Milan, Italy) and 2.5 mg/l amphoteri-
cin B (Sigma-Aldrich; St. Louis; USA). Cells were treated
with IL-2 (100 I.U./ml) (Miltenyi Biotec; Auburn, USA)
+ transforming growth factor beta-1 (TGF-β1) (5 ng/ml)
(PeproTech EC Ltd.; London, UK) (NT) and in the ab-
sence or in the presence of different dosages of budeso-
nide (Bud) and formoterol (For) either alone or in
combination (Bud 1 and 0.01 μM, For 30 and 0.3 nM
and Bud 1 μM+ For 30 nM and Bud 0.01 μM+ For 0.3
nM) (Astrazeneca; Basiglio, Italy) [16, 17]. Cell viability
was evaluated by trypan blue exclusion dye assay to rule
out drugs toxicity. Drugs concentrations have been
chosen considering dose–response experiments from
our previous study on NK cells population in COPD pa-
tients [15]. Following drugs stimulation, cells were har-
vested, resuspended in PBS, stained with antibodies and
analyzed by flow cytometry (time t1) as above described.
In order to exclude a drug solvent effect on cells, the effect
of the maximum EtOH dose used to dissolve the drugs
was also evaluated. We analyzed CD4+CD25highCD127-
cells population by flow cytometry.
Population sample and data analysis
Population sample was estimated according with available
literature and study power calculation. The Kolmogorov-
a – Lymphocyte gate b – CD4+ gate
c - NSHV d - CSHV e - FSC f - CSC
Fig. 1 Gating strategy for flow cytometric identification of CD4+CD25highCD127- regulatory T-cells in the peripheral blood. a Lymphocytes were
identified based on their characteristic properties shown in the forward scatter (FSC) and sideward scatter (SSC). b A representative gating was
set for CD4+ T cells from blood lymphocytes. c A representative dot plots showing expression of CD25highCD127- regulatory T-cells in blood CD4+
T-cells of a never-smoker healthy volunteer (NSHV). d A representative dot plots showing expression of CD25highCD127- regulatory T-cells in blood
CD4+ T-cells of a current smoker healthy volunteer (CSHV). e A representative dot plots showing expression of CD25highCD127- regulatory T-cells
in blood CD4+ T cells of a former smoker COPD patient (FSC). f A representative dot plots showing expression of CD25highCD127- regulatory
T-cells in blood CD4+ T-cells of a current smoker COPD patient (CSC)
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Smirnov test was applied for assessing the normality of
the data distribution. Spearman's rank correlation coeffi-
cient was applied to test the correlation between CD4
+CD25highCD127- Treg cells ratios and FEV1 values. For
multiple comparisons, one-way analysis of variance
(ANOVA) was performed, followed by post hoc Duncan’s
test. Statistical significance was defined as a p value below
0.05. Statistical analysis was performed using STATIS-
TICA version 6.0 (StatSoft) and GraphPad Prism version
5.0 (GraphPad Software Inc.).
Results
Demographic characteristics of study population
PBMCs were obtained from 28 moderate (14 current
smokers and 14 former smokers) COPD patients and 20
healthy volunteers (10 current smokers and 10 never-
smoker). Clinical and demographic data of study popula-
tion are reported in Table 1. The mean ages in the pa-
tients groups were statistically significant different than
in the control groups. The unequal sex ratio is in line
with higher prevalence of COPD in men than in women
observed in real life.
Circulating Tregs in COPD patients and healthy
volunteers
The expression of Treg cells (CD4+CD25highCD127-) in
peripheral blood was different among groups (Fig. 2). In
particular CD4+CD25highCD127- percentage was signifi-
cantly reduced in current smokers COPD patients (CSC)
and former smokers COPD patients (FSC) with respect to
healthy volunteers never-smokers and current smokers
(Fig. 2). Correlating CD4+CD25highCD127- percentages to
FEV1 values, we observed a statistically significant correl-
ation (r = 0.6075; p < 0.0001), showing that the lower Treg
cells are circulating in peripheral blood, the greater will be
the FEV1 decline (Fig. 3).
Effect of budesonide and formoterol in cultured PBMCs
Statistical analysis of data shows that CD4+CD25highCD127-
cells in COPD patients have not a statistically significant re-
sponse to budesonide, alone and in combination with
formoterol, compared with healthy volunteers. In fact, no
treatment significantly modulated the proportion of these
cells (Fig. 4). Cell culture supernatants were used to investi-
gate the production of IL-10 by ELISA test (data not
shown). There were no differences in IL-10 production be-
tween groups (p = 0.1051).
No difference with untreated cells was evidenced with
the maximum EtOH dose used.
Discussion
Several mechanisms have been proposed to be involved
in the development of COPD: oxidative stress due to to-
bacco smoking [18], activation of neutrophils and mac-
rophages, apoptosis of endothelial and epithelial cells
[19], defective efferocytosis of residual apoptotic debris
[20], viral infections [21] and genetic susceptibility [22].
Many of these hypothesis ascribe to environmental fac-
tors a central role in the inflammatory response observed
in COPD, nonetheless this inflammatory state is a self-
perpetuating process able to persist for years after









n 10 10 14 14
Age (years) 61.4 57.8 72.5 §§,*** 69.9 §,**
Sex (F/M) 6/4 1/9 1/13 3/11
FEV1 (%predicted) 102.6 ± 8.45 94.6 ± 11.9 61.71 ± 8.2 §§, ** 57.21 ± 7.3 §§,**
COPD chronic obstructive pulmonary disease; FEV1 forced expiratory volume in the 1
st second
Data are presented as mean ± SD
§ = p < 0.05 vs never-smoker healthy volunteers
§§ = p < 0.01 vs never-smoker healthy volunteers
** = p < 0.01 vs current smoker healthy volunteers
*** = p < 0.001 vs current smoker healthy volunteers
Fig. 2 Comparison with the percentages of CD4+CD25highCD127-
regulatory T-cells in the peripheral blood at t0. Data are expressed as
mean ± SEM. ** = p < 0.01; *** = p < 0.001. NSHV: never-smoker
healthy volunteers; CSHV: current smokers healthy volunteers; FSC:
former smoker COPD patients; CSC: current smoker COPD patients
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cessation of smoking. For this reason it has been proposed
that COPD may derive from a shift from the non-specific
innate response present in every smoker toward an adap-
tive immune response and may present an autoimmune
component. Exposure to infections or smoking-induced
lung injury could release sequestered autoantigens and
DNA from apoptotic cells and alter proteins [23]. T lym-
phocytes can recognize these products as foreign antigens
and maintain a prolonged inflammatory state in the
airways in response to self-antigens [24]. Activation of T-
cells is highly controlled by negative regulatory mecha-
nisms. Disturbed homeostasis of regulatory T-cell
population was demonstrated in several pathologies
with autoimmune etiology such as lupus erythemato-
sus, diabetes mellitus and rheumatoid arthritis [25, 26].
A deficiency of regulatory T-cells can weaken the im-
mune tolerance to self-antigens and thereby support a
persistent inflammation mediated by CD8+ cells in
COPD. Lee et al. hypothesized that, in patients with
emphysema, the inflammatory process would be sus-
tained by the presence of anti-elastin autoantibodies
and showed that the Treg population, detected as
CD25highCD62L+ cells, was lower in the lungs and in
the blood of patients compared to healthy subjects [27].
Data concerning regulatory T-cells in COPD patients are
not so numerous and sometimes discordant. In our study
we investigated CD4+CD25highCD127- proportion in per-
ipheral blood, in current and former smokers with moder-
ate airway obstruction COPD patients and current
smokers and never-smokers healthy volunteers. We found
a significant depletion in CD4+CD25highCD127- proportion
Fig. 4 CD4+CD25highCD127- regulatory T-cells after in vitro treatments. PBMCs from never-smoker healthy volunteers (n = 10), current smokers
healthy volunteers (n = 10), former smoker COPD patients (n = 14) and current smoker COPD patients (n = 14) were cultured with/without drugs.
Data are expressed as mean ± SEM and were normalized to the value of the untreated control. * = p < 0.05; ** = p < 0.01 versus NT. NT = cells
treated with TGF-β + IL-2 alone; BUD1 = cells treated with TGF-β + IL-2 and budesonide 1 μM; BUD0.01 = cells treated with TGF-β + IL-2 and
budesonide 0.01 μM; FOR30 = cells treated with TGF-β + IL-2 and formoterol 30 nM; FOR0.3 = cells treated with TGF-β + IL-2 and formoterol 0.3
nM; BUD1 + FOR30 = cells treated with TGF-β + IL-2 and budesonide 1 μM+ formoterol 30nM; BUD0.01 + FOR0.3 = cells treated with TGF-β + IL-2
and budesonide 0.01 μM+ formoterol 0.3 nM. NSHV: never-smoker healthy volunteers; CSHV: current smokers healthy volunteers; FSC: former
smoker COPD patients; CSC: current smoker COPD patients; TGF-β1: transforming growth factor beta-1; IL: interleukin
Fig. 3 Correlation between CD4+CD25highCD127- regulatory T-cells
ratios and FEV1 (%predicted). Linear regression with a 95 % mean
prediction interval. FEV1: forced expiratory volume in the 1
st second
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in COPD patients compared to healthy smokers and
never-smoker subjects. This might reflect a kind of
progression of inflammation status and exhaustion of
anti-inflammatory responses from healthy smokers to
COPD patients. Evaluating Treg population as CD4
+CD25highCD127-, we confirmed data obtained in other
studies [28, 29]. However, our results are in contrast
with the findings of Barcelò et al., showing that no dif-
ferences in CD4+CD25+ Tregs from peripheral blood
were detected among COPD, healthy smokers and con-
trols and with the results of Vargas-Rojas et al. describ-
ing increased levels of Treg cells present in COPD and
smokers subjects compared to healthy ones [6, 30].
These differences may be caused by patients selection
or technical approach to evidence regulatory T-cells.
Moreover, we found statistically significant differences
in mean age between groups. Based on literature, per-
ipheral CD4+CD25highCD127- cells have to increase
with patient’s age, but our data support the opposite.
Thus, we suppose that these results can be mainly re-
lated to COPD pathology [31–34]. Other studies are
necessary to increase the number of samples and to de-
finitively clarify the role of regulatory T-cells in COPD.
Hopefully, pharmacological treatment might restore
the balance between effector T-cells and regulatory T-
cells [35]. Profita et al. evaluated the expression of
FOXP3 in PBMCs from COPD patients after 48 h of in
vitro stimulation with tiotropium and olodaterol. They
reported increased levels of CD4+CD25+FOXP3+ in
treated PBMCs with respect to untreated ones with both
drugs alone or in combination [36].
In our study, stimulated in vitro COPD patients CD4
+CD25highCD127- cells were not modulated by budeso-
nide or formoterol, both alone and in combination.
Interestingly, these cells were significantly modulated by
budesonide treatments in never-smoker and current
smokers healthy volunteers except by Bud 0.01 μM+ For
0.3 nM in NSHV. Yang et al. showed that in patients
with moderate or severe COPD receiving treatment with
50/500 μg of salmeterol/fluticasone propionate twice a
day for 12 weeks, the proportion of FOXP3+ Tregs in
the total CD4+ T-cell population in the peripheral blood
was drastically higher than that before treatment [29].
The different effect of salmeterol/fluticasone and bude-
sonide/formoterol on peripheral Treg cells should be
evaluated considering the different methodological ap-
proach adopted in the studies.
Nevertheless, if future studies will confirm these re-
sults, they should be analyzed bearing in mind the differ-
ent rate of drug-related adverse events, such as
pneumonia, described in clinical research. In fact, among
the potential side effects of inhaled corticosteroid (ICS)
treatments in COPD patients, the use of fluticasone or
fluticasone/salmeterol combination has been associated
with a higher prevalence of pneumonia in the major
long-term studies [37–39]. All ICSs can suppress natural
and adaptive immunity with a potentially greater inhib-
ition of type-1 innate immunity [40]. On the other hand,
no similar increased risk of pneumonia has been re-
ported in patients with COPD treated with the budeso-
nide/formoterol combination [41–43].
Conclusions
Our data pointed out a different behavior of CD4
+CD25highCD127- T-cells in the four groups evaluated, de-
pending on the presence of COPD inflammatory process.
In COPD patients, Treg cells appeared unsusceptible to
the action of drugs, whose effect is, on the contrary, clear
on cellular components of healthy subjects.
In conclusion, we support the possible role of CD4
+CD25highCD127- in COPD pathogenesis. Budesonide
and formoterol tested in vitro did not have any effects
on CD4+CD25highCD127- population in our experimen-
tal conditions. These results need to further be explored
in a direct comparison with other bronchodilators and
ICSs in order to better clarify their immunomodulatory
properties.
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